Tech Company Financing Transactions
Ensoma Funding Round
Bioluminescence Ventures, Delos Capital and Kite Pharma participated in a $50 million Series B venture round for Ensoma. The round was announced by the company on 5/16/2023.
Transaction Overview
Company Name
Announced On
5/16/2023
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Proceeds Purpose
These investors joined a syndicate of healthcare funds to advance the development of Ensoma's Engenious� in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Kneeland St. 14th Floor
Boston, MA 02111
USA
Boston, MA 02111
USA
Phone
Undisclosed
Website
Email Address
Overview
At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of our Engenious vectors, we can deliver, for the first time, in vivo stem cell modification technologies without the need for prior conditioning or stem cell collection.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Paula Soteropoulos
Chief Executive Officer
Kush Parmar
Chief Scientific Officer
Robert Peters
Chief Technical Officer
Daniel Leblanc
VP - Bus. Development
Naina Bhasin
VP - Regulatory Affairs
Patrick Au
Browse more venture capital transactions:
Prev: 5/16/2023: Jenfi venture capital transaction
Next: 5/16/2023: Kustomer venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs